• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • Sponsored Placement
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

PharmaMar to Present Data on Anticancer Candidates PM1183 and plitidepsin at the AACR Annual Meeting 2015


News provided by

PharmaMar

Apr 14, 2015, 07:45 ET

Share this article

Share this article


MADRID, April 14, 2015 /PRNewswire/ --

  • Combination of the anticancer drug PM1183 with PARP inhibitors and doxorubicin results in a synergistic effect against breast cancer cell lines and a SCLC mouse tumor model, respectively. 
  • The anticancer candidate plitidepsin binds to eEF1A2, a novel therapeutic target in multiple myeloma, and shows activity in patient-derived tumor mouse models from a wide range of solid tumors and hematological cancers. 
  • The new antibody-drug conjugate (ADC), MI130004, shows in vivo potent and long-lasting anticancer effects in breast tumors overexpressing HER2 
Zeltia Logo (PRNewsFoto/PharmaMar)
Zeltia Logo (PRNewsFoto/PharmaMar)
Pharma Mar SA (PRNewsFoto/Pharma Mar SA)
Pharma Mar SA (PRNewsFoto/Pharma Mar SA)
Zeltia Logo (PRNewsFoto/PharmaMar) Pharma Mar SA (PRNewsFoto/Pharma Mar SA)

PharmaMar announces that it will present several abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2015, which will take place in April 18-22 in Philadelphia. This year this important cancer forum will highlight the theme "Bringing Cancer Discoveries to Patients," which underlines the important bridge that connects research discoveries and new treatments. PharmaMar abstracts will underscore advances recently made by the Company that have uncovered new targets and therapeutic approaches and how these discoveries can slow down and in some cases block tumor progression in several tumor models.


    (Logo: http://photos.prnewswire.com/prnh/20150203/727958-a )


    (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )

The studies presented by the Company include the discovery of a new therapeutic target of plitidepsin, the protein eEF1A2. The drug candidate plitidepsin specifically binds to eEF1A2, inducing tumor cell killing in solid and hematological cancers. In addition, combination studies of the breakthrough drug molecule PM1183 with either PARP inhibitors or doxorubicin will be presented to highlight the synergistic effect in relevant preclinical models. Finally, a study showing the in vivo efficacy for the new ADC MI130004 in breast tumor models overexpressing HER-2 will be presented, which strongly suggest the clinical potential of this product candidate.

"Our priority remains improving lives and treatment outcomes for patients with cancer.  We are committed to  the discovery of new targets and innovative therapeutic options," says Carmen Cuevas, PhD, R&D Director at PharmaMar. "The  new data  we are presenting onPM1183 demonstrate  that we are  identifying  new  mechanisms of action." 

Studies to be presented at AACR 2015 

PM1183 

The anticancer therapy PM1183 selectively targets activated transcription, as previously shown at the EORTC-NCI AACR 2014 (abstract #47) and blocks the DNA repair pathway called nucleotide excision repair (NER), eventually leading to an accumulation of DNA errors and cell death.

  • Synergistic combination of PM1183 and PARP inhibitors in breast cancer tumor cell lines (Abstract #2520). Poster presentation, Session Experimental and Molecular Therapeutics - Combination Chemotherapy 1, Monday, April 20th, 1:00 PM - 5:00 PM, Poster section 27

Lead author Juan Fernando Martinez-Leal, PhD will be at the AACR to address the media 

Building on its mechanism of action targeting DNA repair, PharmaMar is presenting the synergistic activity of PM1183 in combination with PARP inhibitors, which targets a different DNA repair. These data are encouraging as the combination therapy of PM1183 with PARP inhibitors may be used to increase tumor cell killing in breast cancer.

  • Combination of PM1183 with doxorubicin induces a synergistic antitumor activity in SCLC tumor xenografts (Abstract #2542). Poster presentation, Session Experimental and Molecular Therapeutics - Combination Chemotherapy 1, Monday, April 20th, 1:00 PM - 5:00 PM, Poster section 27

Lead author Pablo Avilés, PhD will be at the AACR to address the media 

The data from this study in mice bearing SCLC tumors show that the combination of PM1183 with the chemotherapeutic doxorubicin induces synergistic antitumor activity. These data have provided the rationale for the start of a clinical study with this combination treatment in patients with SCLC.

Plitidepsin (Aplidin®) 

The phase 3 study evaluating the efficacy of plitidepsin with dexamethasone in patients with refractory/relapsed multiple myeloma is close to completion and the drug is currently being investigated in the clinic in a subtype of T-cell lymphoma.

  • Plitidepsin shows antitumor activity in patient-derived tumor xenografts and hematologic malignancies (Abstract #5252). Poster presentation, Session Experimental and Molecular Therapeutics - Novel Targets 1, Tuesday, April 21st, 1:00 PM - 5:00 PM, Poster section 30

Lead author Heiner FiebigL, MD, PhD will be at the AACR to address the media 

Data from this study show the antitumor activity of plitidepsin in 23 different tumor types, both solid and hematologic cancers. The broad anticancer activity of plitidipesin across different tumor types is opening new avenues for future clinical studies in different tumor types

  • eEF1A2 is a new target for anticancer therapy (Abstract #5430). Poster presentation, Session Experimental and Molecular Therapeutics - New Targets 2/Novel Assay Technologies, Wednesday, April 22nd, 8:00 AM - 12:00 PM, Poster section 31

Lead author Luis Francisco García-Fernández, PhD will be at the AACR to address the media 

This study further describes how plitidepsin directly interacts with the novel target, the protein eEF1A2, which was recently identified. This protein is overexpressed in tumors, including multiple myeloma. The data support the role of this protein as a novel molecular target in cancer.

ADC MI130004 

A recent breakthrough of the Company is the development of a new ADC, MI130004, which combines the HER2-targeting monoclonal antibody trastuzumab with the marine-derived anticancer agent PM050489.

  • MI130004, a new antibody-drug conjugate, induces a strong, long-lasting antitumor effect in HER2-expressing breast tumor models. (Abstract #2480). Poster presentation, Session Immunology - Antibodies/Antibody Derivatives, Monday, April 20, 1:00 PM - 5:00 PM, Poster section 25

Lead author Carmen Cuevas, PhD will be at the AACR to address the media 

The data underscore the potent and long-lasting activity against HER-expressing breast tumors in mice and the effect in survival. The positive results show great promise for this product.

About PharmaMar 

PharmaMar is a world leader in the discovery and development of marine-based anticancer drugs with a rich pipeline of drug candidates and a strong R&D program. PharmaMar, which is headquartered in Madrid, is a subsidiary of Zeltia, S.A., which has been listed on the Spanish Stock Exchange since 1963 (MSE: ZEL) and on Spain's Electronic Market since 1998. Currently the most advanced clinical programs are PM1183, a novel anticancer agent that prevents tumor progression through different mechanisms of action, including DNA binding to block its replication, inhibition of activated transcription and proteins involved in DNA repair, and the modulation of the tumor microenvironment; and plitidepsin, an anticancer drug that targets eEF1A2 leading to increase in apoptotic death. PM1183 is currently in late-stage development for small-cell lung cancer, BRCA1/2-mutated breast cancer and platinum-resistant ovarian cancer. Plitidepsin is in a phase 3 trial with dexamethasone for refractory multiple myelomaand in a phase 1 study in triple combination with bortezomib for this same indication.

Disclaimer 

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Contact:
PharmaMar Media Relations:
Carolina Pola
Phone: +34-91-846-6108
Mobile: +34-608-93-36-77

Zeltia Investor Relations:
Phone: +34-914444500

SOURCE PharmaMar

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.